FATE Q2 2023 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$933,000-95.0% YoY

Gross Profit

-$40M-4281.1% margin

Operating Income

-$63M-6705.8% margin

Net Income

-$53M-5654.3% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

-98.4%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$31M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$585M

Total Liabilities

$147M

Stockholders' Equity

$438M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$933,000	$19M	-95.0%
Gross Profit	-$40M	-$63M	+36.4%
Operating Income	-$63M	-$83M	+24.7%
Net Income	-$53M	-$76M	+30.7%

Revenue Segments

Upfront Fee And Equity Premium

$31M100%